- Liz Highleyman | 2 hours ago
After three years, tenofovir alafenamide (TAF) for
first-line HIV treatment was better at suppressing viral load and safer for the
bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers
reported at ...
- Liz Highleyman | 23 March 2017
HIV and its monkey cousin
SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope,
which helps the virus enter gut cells during early infection, according to
research presented at the ...
- Keith Alcorn | 22 March 2017
People with HIV who attended their clinic once every six months were much less likely to miss their next clinic visit, miss medication pick up or become lost to follow-up ...
- Keith Alcorn | 17 March 2017
Specialised services to attract men to HIV testing and treatment may need to adopt several different formats in order to reach different sub-populations of men, suggesting there is no single ...
- Keith Alcorn | 16 March 2017
Almost one in five people newly diagnosed with HIV in
a study employing active methods to link people to care and treatment had still
not linked to care a year after diagnosis, ...
- Liz Highleyman | 15 March 2017
This year's Conference on
Retroviruses and Opportunistic Infections (CROI 2017), held last month in Seattle,
included presentations on several new investigational antiretroviral drugs in
development, reflecting a more robust pipeline than we have ...
- Liz Highleyman | 14 March 2017
People with HIV often show persistent signs of cognitive impairment and
abnormalities in brain structure despite suppressive antiretroviral therapy
(ART), but they do not appear to experience accelerated decline compared to
HIV-negative people ...
- Keith Alcorn | 13 March 2017
After a second wave of intensive household testing, a large
study of the 'test and treat' strategy in Zambia is diagnosing more people with
HIV, getting more people onto treatment and reducing ...
- Liz Highleyman | 10 March 2017
glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact
with or require dose adjustment when taken with commonly used antiretroviral
regimens, offering a new option for people with HIV/hepatitis C ...
- Liz Highleyman | 09 March 2017
Dolutegravir used alone without other antiretrovirals
was unable to keep viral load suppressed in some people who switched from a
standard three-drug combination regimen, according to research presented at the
2017 Conference on ...
- Liz Highleyman | 08 March 2017
People with HIV/hepatitis C virus (HCV) co-infection with
liver cirrhosis or liver failure, and those who received liver transplants, saw
high rates of sustained virological response using interferon-free
direct-acting antiviral (DAA) therapy for ...
- Michael Carter | 08 March 2017
Long-term use of
the protease inhibitor darunavir/ritonavir modestly increases the risk of
cardiovascular disease, according to data from the ongoing D:A:D study
presented to the recent Conference on Retroviruses and Opportunistic Infections
(CROI 2017). ...
- Roger Pebody | 07 March 2017
Seven simple questions about symptoms and risk factors
identified three-quarters of gay men in Amsterdam who have acute (very recent)
HIV infection, according to a study presented at the Conference on Retroviruses ...
- Liz Highleyman | 06 March 2017
An HIV-positive bone marrow
transplant recipient at the Mayo Clinic experienced prolonged viral remission
lasting nearly 10 months – longer than the so-called Boston patients – after
interrupting antiretroviral therapy (ART), according to ...
- Liz Highleyman | 03 March 2017
A novel type of antiretroviral drug that
interferes with the assembly and disassembly of the HIV capsid, which encloses
the genetic blueprint of the virus, may offer a new potent and long-acting
- Gus Cairns | 02 March 2017
HIV-2’s virulence may have been underestimated and although progression to AIDS and death in HIV-2 infection was slower than with HIV-1, it was the rule rather than the exception, new ...
- Keith Alcorn | 01 March 2017
HIV integrase inhibitors such as dolutegravir and raltegravir may increase the risk of immune reconstitution inflammatory syndrome (IRIS), studies from the Netherlands and France presented last month at the Conference ...
- Liz Highleyman | 27 February 2017
People with HIV and hepatitis C virus (HCV) co-infection who are
successfully treated for hepatitis C using interferon-free direct-acting
antiviral (DAA) therapy do not appear to have an increased likelihood of
developing hepatocellular ...
- Gus Cairns | 23 February 2017
Research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) found that the efficacy of oral
pre-exposure prophylaxis (PrEP) for women was not affected by bacterial vaginosis (BV) – ...
- Liz Highleyman | 22 February 2017
A pair of long-acting monoclonal antibodies that
prevent HIV from entering human cells – ibalizumab and PRO 140 – may offer new
treatment options for people with highly resistant virus and limited ...